European Commission has approved BYANNLI from Johnson & Johnson. The drug, administered every 6 months, is intended for the therapy of schizophrenia in adults. Studies have shown that BYANNLI PP6M is just as effective as PP3M, the version of the drug that must be given every 3 months.
European Commission has approved BYANNLI from Johnson & Johnson. The drug, administered every 6 months, is intended for the therapy of schizophrenia in adults. Studies have shown that BYANNLI PP6M is just as effective as PP3M, the version of the drug that must be given every 3 months. 
johnsonandjohnson.gcs-web.com
English (US) 